GLP-1 Receptor Agonists Linked to Reduced Risk for Developing Uveitis
GLP-1 RAs linked to lower risk among those with type 2 diabetes and without diabetes; greater protection seen versus metformin, insulin
Jim O’Neill Steps in as Acting CDC Chief Amid Firing, Resignations
CVS, Walgreens Limit COVID Vaccines in Some States as Rules Shift
FDA Approves Subcutaneous Leqembi for Treatment of Early Alzheimer Disease
Leqembi Iqlik allows for at-home maintenance dosing after initial 18 months of intravenous dosing
Cannabis-Based Medical Products Aid Primary Insomnia
Findings seen in as little as one month of treatment through 18 months of treatment
Environmental Benefit Seen With GLP-1 Receptor Agonist Use in Heart Failure
Heart failure event-related greenhouse gas emissions estimated at 9.45 and 9.70 kg CO2e per patient per year for GLP-1 RA and placebo users, respectively
Type of Hormone Therapy Used After Menopause Affects Memory Performance
Transdermal estradiol MHT linked to higher episodic memory scores, oral estradiol linked to higher prospective memory scores
FDA Now Providing Daily Updates on Adverse Events
To increase transparency, the agency is publishing data from the FDA Adverse Event Reporting System daily rather than quarterly
AI-Enabled Bundle of Sensors, Coaching Aids Type 2 Diabetes Outcomes
Significant improvements seen in glycemic control, weight loss, and de-escalation of glucose-lowering pharmacotherapy versus usual care
Spironolactone Does Not Reduce Risk for Cardiovascular Morbidity, Mortality in Patients on Dialysis
No reduction seen in the composite outcome of cardiovascular mortality, hospitalization due to heart failure
